Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301

PURPOSE: We sought to characterize the pharmacokinetics (PK) and determine a tolerable dose of oral sorafenib in patients with hepatic or renal dysfunction. PATIENTS AND METHODS: Patients were assigned to one of nine cohorts: cohort 1, bilirubin ≤ upper limit of normal (ULN) and AST ≤ ULN and creati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Miller, Antonius A., Murry, Daryl J., Owzar, Kouros, Hollis, Donna R., Kennedy, Erin B., Abou-Alfa, Ghassan, Desai, Apurva, Hwang, Jimmy, Villalona-Calero, Miguel A., Dees, E. Claire, Lewis, Lionel D., Fakih, Marwan G., Edelman, Martin J., Millard, Fred, Frank, Richard C., Hohl, Raymond J., Ratain, Mark J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2009
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2668705/
https://ncbi.nlm.nih.gov/pubmed/19255312
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.0931
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados